Aerodigestive cancers in HIV infection

Missak Haigentz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose of review: Aerodigestive (lung, head and neck) cancers are among the most prevalent and deadly neoplasms worldwide, and the incidence rates are rising. Given the improvements in life expectancy of persons with HIV/AIDS when treated with highly active antiretroviral agents, persons with HIV infection are therefore increasingly likely to develop these malignancies. This chapter focuses on the epidemiology of these malignancies and reviews the most recent literature and current understanding of the causes and treatment of these malignancies in HIV-positive populations. Recent findings: Aerodigestive neoplasms in patients with HIV infection are associated with younger age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. The causes of these cancers, aside from the traditional risk factors of tobacco and alcohol exposure, are not clear. Although these neoplasms are non-AIDS defining, factors that might contribute to risk include HIV-related immunosuppression and co-infection with high-risk human papillomavirus subtypes. Summary: With continued improvements in therapies for HIV, the expected increase in incidence and mortality of persons with HIV infection from aerodigestive malignancies will likely become a major public health concern. Given the younger age of HIV-infected patients with these malignancies and the apparently higher rates of smoking among HIV-positive individuals, aggressive smoking cessation efforts should be directed to this high-risk population.

Original languageEnglish (US)
Pages (from-to)474-478
Number of pages5
JournalCurrent Opinion in Oncology
Volume17
Issue number5
DOIs
StatePublished - Sep 2005

Fingerprint

HIV Infections
HIV
Neoplasms
Smoking
Anti-Retroviral Agents
Incidence
Smoking Cessation
Head and Neck Neoplasms
Life Expectancy
Coinfection
Immunosuppression
Population
Tobacco
Acquired Immunodeficiency Syndrome
Epidemiology
Public Health
Alcohols
Lung
Mortality
Therapeutics

Keywords

  • Acquired immunodeficiency syndrome
  • Head and neck cancer
  • Human immunodeficiency virus
  • Human papillomavirus
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Aerodigestive cancers in HIV infection. / Haigentz, Missak.

In: Current Opinion in Oncology, Vol. 17, No. 5, 09.2005, p. 474-478.

Research output: Contribution to journalArticle

Haigentz, Missak. / Aerodigestive cancers in HIV infection. In: Current Opinion in Oncology. 2005 ; Vol. 17, No. 5. pp. 474-478.
@article{89a4f0c8c76c44c9ae1dc227cd11b35c,
title = "Aerodigestive cancers in HIV infection",
abstract = "Purpose of review: Aerodigestive (lung, head and neck) cancers are among the most prevalent and deadly neoplasms worldwide, and the incidence rates are rising. Given the improvements in life expectancy of persons with HIV/AIDS when treated with highly active antiretroviral agents, persons with HIV infection are therefore increasingly likely to develop these malignancies. This chapter focuses on the epidemiology of these malignancies and reviews the most recent literature and current understanding of the causes and treatment of these malignancies in HIV-positive populations. Recent findings: Aerodigestive neoplasms in patients with HIV infection are associated with younger age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. The causes of these cancers, aside from the traditional risk factors of tobacco and alcohol exposure, are not clear. Although these neoplasms are non-AIDS defining, factors that might contribute to risk include HIV-related immunosuppression and co-infection with high-risk human papillomavirus subtypes. Summary: With continued improvements in therapies for HIV, the expected increase in incidence and mortality of persons with HIV infection from aerodigestive malignancies will likely become a major public health concern. Given the younger age of HIV-infected patients with these malignancies and the apparently higher rates of smoking among HIV-positive individuals, aggressive smoking cessation efforts should be directed to this high-risk population.",
keywords = "Acquired immunodeficiency syndrome, Head and neck cancer, Human immunodeficiency virus, Human papillomavirus, Lung cancer",
author = "Missak Haigentz",
year = "2005",
month = "9",
doi = "10.1097/01.cco.0000174036.46785.8f",
language = "English (US)",
volume = "17",
pages = "474--478",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Aerodigestive cancers in HIV infection

AU - Haigentz, Missak

PY - 2005/9

Y1 - 2005/9

N2 - Purpose of review: Aerodigestive (lung, head and neck) cancers are among the most prevalent and deadly neoplasms worldwide, and the incidence rates are rising. Given the improvements in life expectancy of persons with HIV/AIDS when treated with highly active antiretroviral agents, persons with HIV infection are therefore increasingly likely to develop these malignancies. This chapter focuses on the epidemiology of these malignancies and reviews the most recent literature and current understanding of the causes and treatment of these malignancies in HIV-positive populations. Recent findings: Aerodigestive neoplasms in patients with HIV infection are associated with younger age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. The causes of these cancers, aside from the traditional risk factors of tobacco and alcohol exposure, are not clear. Although these neoplasms are non-AIDS defining, factors that might contribute to risk include HIV-related immunosuppression and co-infection with high-risk human papillomavirus subtypes. Summary: With continued improvements in therapies for HIV, the expected increase in incidence and mortality of persons with HIV infection from aerodigestive malignancies will likely become a major public health concern. Given the younger age of HIV-infected patients with these malignancies and the apparently higher rates of smoking among HIV-positive individuals, aggressive smoking cessation efforts should be directed to this high-risk population.

AB - Purpose of review: Aerodigestive (lung, head and neck) cancers are among the most prevalent and deadly neoplasms worldwide, and the incidence rates are rising. Given the improvements in life expectancy of persons with HIV/AIDS when treated with highly active antiretroviral agents, persons with HIV infection are therefore increasingly likely to develop these malignancies. This chapter focuses on the epidemiology of these malignancies and reviews the most recent literature and current understanding of the causes and treatment of these malignancies in HIV-positive populations. Recent findings: Aerodigestive neoplasms in patients with HIV infection are associated with younger age at diagnosis, cigarette smoking, advanced stage at presentation, and a more aggressive clinical course. The causes of these cancers, aside from the traditional risk factors of tobacco and alcohol exposure, are not clear. Although these neoplasms are non-AIDS defining, factors that might contribute to risk include HIV-related immunosuppression and co-infection with high-risk human papillomavirus subtypes. Summary: With continued improvements in therapies for HIV, the expected increase in incidence and mortality of persons with HIV infection from aerodigestive malignancies will likely become a major public health concern. Given the younger age of HIV-infected patients with these malignancies and the apparently higher rates of smoking among HIV-positive individuals, aggressive smoking cessation efforts should be directed to this high-risk population.

KW - Acquired immunodeficiency syndrome

KW - Head and neck cancer

KW - Human immunodeficiency virus

KW - Human papillomavirus

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=24044536161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044536161&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000174036.46785.8f

DO - 10.1097/01.cco.0000174036.46785.8f

M3 - Article

VL - 17

SP - 474

EP - 478

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -